P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Table 5

One-year rates of adverse events in propensity matched population.

	Clopidogrel		Ticagrelor			Clopidogrel		Prasugrel
	(N = 1704)		(N = 570)			(n = 1503)		(n = 501)
Mortality	47	2.8	12	2.1	0.41	37	2.5	18	3.6	0.18
MI	75	4.4	31	5.5	0.31	42	2.8	22	4.4	0.08
Stroke	22	1.3	12	2.1	0.16	22	1.5	7	1.4	0.93
Bleeding events	33	1.9	17	3.0	0.14	33	2.2	14	2.8	0.44

Evaluated using the log-rank test with comparison group of clopidogrel.